Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials

Circulation

Volumn 106, Issue 24, 2002, Pages 3063-3067

  Roffi, Marco ^a   Mukherjee, Debabrata ^c   Chew, Derek P ^d   Bhatt, Deepak L ^b   Cho, Leslie ^b   Robbins, Mark A ^e   Ziada, Khaled M ^b   Brennan, Danielle M ^b   Ellis, Stephen G ^b   Topol, Eric J ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e St Thomas Hospital   (United States)

Author keywords

Angioplasty; Bypass; Glycoproteins; Platelets; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; EMBOLISM PREVENTION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; CORONARY ARTERY BYPASS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; REOPERATION; STENTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037058871     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000041250.89627.A9     Document Type: Article

References (24)

1. Barner HB, Barnett MG. Fifteen- to twenty-one-year angiographic assessment of internal thoracic artery as a bypass conduit. Ann Thorac Surg. 1994;57:1526-1528.
2. Bourassa MG, Enjalbert M, Campeau L, et al. Progression of atherosclerosis in coronary arteries and bypass grafts: Ten years later. Am J Cardiol. 1984;53:102C-107C.
3. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-626.
4. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation. 1994; 89:2514-2518.
5. de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol. 1993;21:1539-1549.
6. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-1115.
7. Bairn DS, Wahr D, George B, et al. Randomized trial of distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
8. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
10. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92.
11. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-1428.
12. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339:436-443.
13. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
14. Bhatt DL, Topol EJ. Percutaneous coronary intervention for patients with prior bypass surgery: Therapy in evolution. Am J Med. 2000;108:176-177.
15. Loop FD, Lytle BW, Cosgrove DM, et al. Reoperation for coronary atherosclerosis: Changing practice in 2509 consecutive patients. Ann Surg. 1990;212:378-385.
16. Lytle BW, Loop FD, Cosgrove DM, et al. Fifteen hundred coronary reoperations: Results and determinants of early and late survival. J Thorac Cardiovasc Surg. 1987;93:847-859.
17. Hong MK, Mehran R, Dangas G, et al. Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol. 2001;38:150-154.
18. Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts: EPIC investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am J Cardiol. 1997;80:985-988.
19. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol. 1998;32:1619-1623.
20. Mathew V, Grill DE, Scott CG, et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol. 1999;34:1163-1169.
21. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation. 1998;97:916-931.
22. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
23. Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation. 2001;104:2436-2441.
24. Savage MP, Douglas JS, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med. 1997;337:740-747.